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Inflammation is a complex process that implies the interaction between cells and molecular mediators, which, when not properly
“tuned,” can lead to disease. When inflammation affects the eye, it can produce severe disorders affecting the superficial and
internal parts of the visual organ. The nucleoside adenosine and nucleotides including adenine mononucleotides like ADP and
ATP and dinucleotides such as P1,P4-diadenosine tetraphosphate (Ap
4
A), and P1,P5-diadenosine pentaphosphate (Ap
5
A) are
present in different ocular locations and therefore they may contribute/modulate inflammatory processes. Adenosine receptors,
in particular A
2A adenosine receptors, present anti-inflammatory action in acute and chronic retinal inflammation. Regarding the
A
3
receptor, selective agonists likeN6-(3-iodobenzyl)-5󸀠-N-methylcarboxamidoadenosine (CF101) have been used for the treatment
of inflammatory ophthalmic diseases such as dry eye and uveoretinitis. Sideways, diverse stimuli (sensory stimulation, large
intraocular pressure increases) can produce a release of ATP from ocular sensory innervation or after injury to ocular tissues.Then,
ATP will activate purinergic P2 receptors present in sensory nerve endings, the iris, the ciliary body, or other tissues surrounding
the anterior chamber of the eye to produce uveitis/endophthalmitis. In summary, adenosine and nucleotides can activate receptors
in ocular structures susceptible to suffer from inflammatory processes. This involvement suggests the possible use of purinergic
agonists and antagonists as therapeutic targets for ocular inflammation.
1. Introduction
Inflammation is the biological process triggered when a
vascular tissue needs to be repaired from an injury or faces
a microbial challenge. This process is normally self-limited;
however, in the absence of a proper return to homeostasis it
can turn into a damaging condition for tissues [1, 2]. It works
throughout complex and specific interactions between cells
and mediator molecules in the damaged tissue that require
a fine and well-tuned molecular regulation. In the absence
of a prompt resolution of the acute inflammatory response,
affected tissue may progress to a chronic inflammatory status
that leads to disease [3].
As many organs, human eye suffers important and
sometimes devastating inflammatory diseases. In such cases,
inflammation can be either cause or consequence of disorders
affecting different structures in the anterior part of the eye,
the intraocular compartment, or both. Examples of such con-
ditions include lacrimal keratoconjunctivitis, severe allergic
diseases, severe cicatrizing conjunctivitis, uveitis (intraocular
inflammation of the uvea, retina, vitreous body, and/or
optic nerve head), age-relatedmacular degeneration, diabetic
retinopathy, and its major complication, and proliferative
vitreoretinopathy. Also, it is important to note that ocular
infections, traumas, and surgery also involve inflammatory
processes that can lead to a vision-threatening situation if
not properly controlled. Many efforts have been invested in
the development of therapeutic strategies to confront such
diseases (for recent reviews see [4–6]), even using the aid of
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novel technology-related strategies, such as drug delivery sys-
tems or gene therapy (for recent reviews see [7, 8]). However,
a much deeper knowledge of molecular pathophysiology
mechanisms andmediators underlying ocular inflammation-
related disorders is necessary.
The eye has its own mechanism to protect itself from
inflammation, which is the so called immune privilege [9].
The biological significance of such “privilege” is the active
tolerance to foreign antigens exerted by the ocular immune
system. In addition, the tightly sealed blood-ocular barriers
prevent the passage of inflammatory cells andmolecules from
the blood into the eye. Altogether, the collateral inflamma-
tion that is associated with the normal immune response
is avoided. However, the immune privilege can fail and
inflammation can eventually develop with the involvement of
different mediators.
There are several families of molecules that have been
described as active participants in ocular inflammatory dis-
eases.These include immunemediators such as cytokines and
chemokines and enzymes such as matrix metalloproteinases,
lipids, growth factors and their receptors, and neurotransmit-
ters and their receptors. These last ones are especially inter-
esting because they are involved in maintaining the immune
privilege [10], among other physiological activities. Different
neuropeptides and their receptors have been identified in
ocular structures, including the cornea, sclera, iris, ciliary
body, ciliary process, and the retina [11]. In addition, there are
examples of the involvement of not only neuropeptides, but
also biogenic amines, amino acids, acetylcholine, or purines,
in physiological processes of the eye that can be affected by
inflammation.Thus, the knowledge of the clinical impact that
neuropeptides and their receptors may have is growing in
parallel with their envisioned therapeutical applications in
ocular inflammatory diseases.
The role of parasympathetic and sympathetic nerves in
conjunctival goblet cell functioning has been reported (for
review see [12]).The parasympathetic nerves contain the neu-
rotransmitters acetylcholine and vasoactive intestinal peptide
(VIP), and the sympathetic nerves contain norepinephrine
and neuropeptide Y. Also, purinergic receptor P2Y
2
agonists,
such as UTP and ATP, are capable of stimulating both goblet
cell mucin secretion and stratified squamous cell fluid (water
and electrolytes) secretion to tear film [12]. Sensory nerves
of cornea and conjunctiva contain neurotransmitters such
as substance P, calcitonin gene-related peptide, and galanin,
which can activate a neural reflex to stimulate conjunctival
goblet cell secretion [13]. The reduction in corneal sensation
that takes place in chronic inflammatory disease of the
ocular surface can impair the secretion of mucin and water
components of the tear film.
Histamine produced by conjunctival sensitized mast cells
is a well-known mediator of the allergic pathology affecting
the eye [14]. It is secreted to conjunctival tissues and the tear
film, along with other mast cell-derived irritant mediators,
after the allergen challenge and triggers different allergic
inflammation-related processes [15]. It not only increases
vasodilation and vascular permeability to immune cells,
but also directly acts upon specific receptors present in
conjunctival epithelial cells to stimulate goblet cell mucin
secretion [16]. Besides, histamine exerts a chemotactic effect
on various immune cell types through a complex cytokine
network thus amplifying its biological activities.
The eye has a small piece of brain in it, that is, the retina.
It is long known the importance of neurotransmitters and
their receptors for the processing of visual informationwithin
the retinal tissue [17]. Catecholamine neurotransmitters,
mainly dopamine, are key for retinal neuron functioning
in the vertebrate retina. Also, the role exerted by excitatory
and inhibitory amino acids as well as acetylcholine in the
visual process is well established [18]. Glutamate, aspartate,
gamma-aminobutyric acid, taurine, and glycine are normal
neurotransmitter or neuromodulatory agents for photore-
ceptors and other retinal neurons, such as horizontal and
amacrine cells. Mu¨ller cells, the main glial cell of the retina,
also secrete neurotransmitters and express a wide variety
of neurotransmitter receptors, reflecting their participation
in the physiological signaling between neurons and glial
cells [19]. However, glutamate-mediated loss of retinal gan-
glion cells occurs in glaucoma and retinal vessels occlusion
(central and branch retinal artery and retinal vein) [20].
Cooperation between inflammatory cytokines and glutamate
receptors has been proposed as one of the mechanisms
responsible for a toxic damage on retinal cells related to
glutathione depletion [21]. Mu¨ller cells protect neurons from
glutamate toxicity. It is now widely accepted that almost
any retinal degenerative disease is associated with Mu¨ller
cell gliosis, which is a complex series of functional changes
that occurs as a consequence of retinal inflammation accom-
panying the degenerative process. Gliosis impedes Mu¨ller
cell protective role against glutamate toxicity and impairs
their neurotransmitter recycling activity in the glioneuronal
interactions [22].
Among the plethora of transmitters present in the ocular
structures, nucleosides and nucleotides emerge as remarkable
molecules with the ability to regulate many biochemical and
physiopathological processes. Their actions are mediated by
membrane receptors termed purinergic receptors that can
be divided into adenosine P1 or A receptors and nucleotide
receptors named as P2. Adenosine receptors can be divided
into A
1
, A
2A, A2B, and A3 and these receptors are only
sensitive to the nucleoside adenosine. On the contrary, P2
receptors are divided into two main groups, ionotropic P2X
andmetabotropic P2Y receptors, and are sensitive to adenine,
to guanine nucleotides, and also to dinucleotides such as
dinucleoside polyphosphates.
The diversity of receptors in the eye structures reflects
the importance of these molecules in processes such as tear
secretion, intraocular pressure homeostasis, lens accommo-
dation, or retinal functioning. Moreover, use of nucleosides
and nucleotides, naturally occurring and synthetic, has been
suggested to rescue the eye from some pathological con-
ditions. Indeed there is a chance for the development of
patents based on nucleotides as a therapeutic approach since
it has been possible to relate nucleoside/nucleotide levels with
pathological conditions, such as dry eye or glaucoma, for
example. The review of the patent literature did not bring
any document related to ocular inflammatory processes. In
this sense it might be of interest the development of new
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Figure 1: Purinergic receptors identified in the ocular anterior segment. Purinergic receptors localized in the different ocular parts/structures
of the ocular anterior segment are shown.
inventions for the treatment of ocular inflammation based on
purinergic agonists and antagonists.
The scientific literature that studies the relation of purines
and the eye have provided a disperse number of papers
describing the involvement of these molecules in ocular
inflammatory processes. In this sense, the present work
reviews and groups the existing works in the field by struc-
turing them in two main groups, on the one hand, actions
mediated by means of adenosine receptors and on the other
hand those occurring by nucleotide receptors.
2. Adenosine Receptors
Adenosine is elevated at sites of tissue damage resulting from
inflammation or hypoxia [23, 24]. Adenosine can be formed
intracellularly and diffuse into the extracellular space via
equilibrative nucleoside transporter, or extracellularly from
released ATP by ectonucleotidases, CD39 and CD73. Under
stress and ischemic conditions, the local tissue concentration
of extracellular adenosine is increased due to its synthesis
from the released ATP. Adenosine has been proposed to
modulate a variety of physiological responses including
inflammation and immunity by stimulating specific adeno-
sine receptors (AR) [25, 26]. To date, four adenosine receptor
subtypes A
1
, A
2A, A2B, and A3 have been identified that
belong to the family of seven transmembrane G protein-
coupled receptors [27]. The A
1
and A
3
adenosine receptors
preferentially couple to Gi protein to inhibit adenylate cyclase
and consequently the production of cyclic AMP (cAMP),
and the A
2A and A2B subtypes stimulate the production of
cAMP by coupling to Gs. Expression of adenosine receptors
has been described in different eye locations (Figure 1).
The presence of A
2B adenosine receptors [28] has been
detected on bovine corneal endothelium. In the ciliary
epithelium, A
1
, A
2A, and A2B adenosine receptor mRNAs
were found in the ciliary processes of rat using in situ
hybridization [29]. Later, A
3
adenosine receptor mRNA
expression was also detected in cultured human ciliary
epithelial cells and rabbit ciliary processes by RT-PCR [30].
In the retina, A
2A adenosine receptor mRNA expression was
mainly found in the inner nuclear layer and ganglion cell layer
and to a lesser extent in the outer nuclear layer. Likewise,
A
1
and A
3
adenosine receptor mRNAs were identified in the
ganglion cell layer of the retina [29, 31]. In addition, A
2A and
A
2B adenosine receptors are also present in retinal pigment
epithelial cells [29, 32] as well as in Mu¨ller cells [33].
2.1. A
1
Adenosine Receptors. Conflicting conclusions about
the effect of A
1
adenosine receptors on inflammation have
been reported. Thus, A
1
adenosine receptor has been impli-
cated as a potent anti-inflammatory mediator in various
inflammatory models of several organ systems, including the
kidney [34], heart [35], liver [36], and brain [37]. On the
contrary, in the lung, pharmacologic blocking of A
1
adeno-
sine receptors attenuated lipopolysaccharide (LPS)-induced
lung injury in cats [38]. Likewise, in an allergic mouse
model of asthma, A
1
adenosine receptors have been shown
responsible for altered vascular reactivity, increased airway
hyperresponsiveness, and systemic inflammation [39].
In the eye, there is no data about the role of this receptor
in ocular inflammation. To date, it has been only showed
that A
1
adenosine receptor mediates IL-6 trophic effect on
retinal ganglion cells [40]. IL-6 is a pleiotropic cytokine
classically denominated proinflammatory, but, additionally,
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it has been demonstrated that this cytokine is able to increase
the survival of retinal ganglion cells [41]. It remains unknown
whether A
1
adenosine receptor could also take part in some
proinflammatory actions induced by this cytokine in the
retina apart from the IL-6 trophic effect on retinal ganglion
cells.
2.2. A
2𝐴
Adenosine Receptors. Substantial lines of evidence
have suggested that the anti-inflammatory effects of extracel-
lular adenosine aremainlymediated by A
2A adenosine recep-
tors [25, 42]. The anti-inflammatory action of A
2A adenosine
receptors in acute and chronic retinal inflammation has been
demonstrated [43, 44]. Using cultured retinal microglia cells
activated by LPS as an in vitro model of acute neuroinflam-
mation, Liou et al. [44] showed that A
2A adenosine receptor
activation in the stressed retinal microglial cells efficiently
inhibited LPS-induced TNF-𝛼 release. The protective role
of A
2A adenosine receptor in chronic retinal inflammation
associated to diabetic retinopathy has also been examined
[43, 45]. Diabetic retinopathy has been categorized as a
vascular-neuroinflammatory disease. Among the early signs
of diabetic retinopathy are retinal inflammatory reactions,
breakdown of the blood-retinal barrier function, and loss
of retinal neurons [46–48]. As the disease progresses, the
retina may be damaged by oxidative stress induced by hyper-
glycemia, or advanced glycation end products [49, 50]. This
stress damages vascular and neuronal tissues of the retina
and activatesmicroglial cells [51]. Activatedmicroglia further
exacerbate the damage by releasing cytotoxic molecules
(glutamate, reactive oxygen species) and proinflammatory
mediators, such as TNF-𝛼 [52, 53]. Thus, local inflamma-
tion has a relevant contribution in the pathogenesis of
diabetic retinopathy. To elucidate the role of A
2A adenosine
receptor in diabetic retinopathy, the effect of A
2A adeno-
sine receptor ablation on diabetic mice was analyzed [43].
Knockout A
2A adenosine receptor mice had significantly
more retinal terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL)-positive cells, TNF-𝛼 release,
and intercellular adhesion molecule 1 (ICAM-1) expression
compared with diabetic wild type [43]. Interestingly, together
with these changes, an altered microglia phenotype was
observed in the knockout A
2A adenosine receptor mice.
In this sense, in a diabetic milieu, microglia transformed
from their ramified resting state into an amoeboid shape,
the activated and cytokine-releasing state, and this pheno-
typic configuration was more evident in the knockout A
2A
adenosine receptor diabetic mice than in diabetic wild-type
[43]. Moreover, treatment of diabetic mice with the A
2A
adenosine receptor agonist CGS21680 (3-[4-[2-[[6-amino-9-
[(2R, 3R, 4S, 5S)-5-(ethylcarbamoyl)-3,4-dihydroxy-oxolan-
2-yl]purin-2-yl]amino]ethyl]phenyl]propanoic acid) attenu-
ated the morphological transformation of ramified microglia
into an activated ameboid microglia and resulted in marked
decreases in diabetes-induced retinal cell death and TNF-
𝛼 release [43]. Inhibition of reactive microglial phenotype
acquisition is not the only mechanism by which A
2A adeno-
sine receptor regulates inflammation in diabetic retinopathy.
Additional studies using microglial retinal cells treated with
amadori-glycated albumin (AGA) (a risk factor in diabetic
disorders) showed that activation of A
2A adenosine receptor
attenuated AGA-induced TNF-𝛼 release by repressing the
inflammatory cascade C-Raf/extracellular signal-regulated
kinase (ERK) in activated microglia (Figure 2) [43, 45].
Considering these findings about the protective role
of A
2A adenosine receptor activation in diabetes-induced
retinal inflammation, abnormality in adenosine metabolism
could have influence on retinal complications in diabetic
retinopathy. In this context, an increased expression and
activity of catabolic enzyme adenosine deaminase-2 (ADA2),
which represent a critical checkpoint in the regulation of
extracellular adenosine levels and, consequently, in the con-
trol of receptor stimulation and function, have been identified
in human andporcine retinaswith diabetes aswell as inAGA-
treated porcine and human microglia cells [54]. Moreover,
TNF-𝛼 release was induced in AGA-treated microglia cells
and that TNF-𝛼 release was blocked by ADA2-neutralizing
antibody or ADA2 siRNA [54]. These results confirm that
abnormality in adenosine metabolism can contribute to
retinal inflammation in diabetic retinopathy and suggest that
the anti-inflammatory activity of A
2A adenosine receptor
signaling can be impaired in diabetic retinopathy due to
increased ADA2 activity.
Taking into advance the ability of A
2A adenosine receptor
to offer protection against retinal inflammation in diabetic
retinopathy, the use of the A
2A adenosine receptor agonist
CGS21680 in other ocular retinal pathologies in which proin-
flammatory mediators are released has also been examined
[55]. The A
2A adenosine receptor agonist administration sig-
nificantly attenuated the expression of inflammatory (TNF-
𝛼, IL-6, and ICAM-1) and cell death markers in a mouse
model of traumatic optic neuropathy (a disease characterized
by retinal ganglion cell death, which is closely related to the
local production of reactive oxygen species and inflammatory
mediators from activated microglial cells) [55]. A
2A adeno-
sine receptor agonist anti-inflammatory action was mediated
by blocking ERK activation and subsequent cytokine release
in traumatic optic neuropathy activated microglia cells
(Figure 2).
On the other hand, it has been described the contribution
of adenosinergic pathway throughA
2A adenosine receptor on
protective regulatory immunity in a mouse model of human
autoimmune uveitis [56]. Thus, A
2A adenosine receptor
activation on T cells was associated with antigen-presenting
cells (APC) induction and activation of Tregs (regulatory T
cells), which mediate a postexperimental autoimmune uveo-
retinitis regulatory immune response to ocular autoantigens
protecting from recurrence of uveitis [56].
2.3. A
2𝐵
Adenosine Receptors. Discrepancy between anti-
inflammatory and proinflammatory effects has been
observed in several tissues for A
2B adenosine receptors [57].
This apparent contradiction might be related to differences
between the acute and chronic models of inflammation
studied, playing the receptor different roles at different points
during the progression of inflammation. Furthermore, A
2B
adenosine receptors may play different roles even in similar
types of inflammation but occurring in different tissues
[57–59].
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Figure 2: Regulation of retinal inflammation by A
2A adenosine receptor. Pathways proposed to be involved in anti-inflammatory effect of A2A
adenosine receptor in the retinal microglial cells during pathologies such as diabetes or traumatic optic neuropathy. A
2A adenosine receptor
activation reduces TNF-𝛼 release by repressing the inflammatory cascade C-Raf/ERK in activated retinal microglia.
Little is known about the role of A
2B adenosine receptor
in the eye. A gradual increase in A
2B adenosine receptor
has been reported after alkali burn-induced corneal inflam-
mation and neovascularization. As A
2B adenosine receptor
was not expressed by normal cornea, it suggests that the
A
2B adenosine receptor detected after alkali burns was pro-
duced in the cornea by infiltrated inflammatory cells [60].
In agreement with this finding, it has been detected that
A
2B adenosine receptor seems to be mainly expressed in
inflammatory cells [61].
2.4. A
3
Adenosine Receptors. The A
3
adenosine receptor is
highly expressed in inflammatory cells whereas low or almost
no expression is found in normal cells [62], rendering the
A
3
adenosine receptor as a potential therapeutic target. A
3
adenosine receptor upregulation can be attributed to several
factors, including elevated adenosine and cytokines, which
are characteristic of the microenvironment of inflammatory
cells [63]. Under these conditions, the binding of adenosine
to their cell surface receptors might induce, through an
autocrine pathway, the expression of its own receptors [64,
65]. Additionally, it has been proposed that the proin-
flammatory cytokine TNF-𝛼 can induce an increase of the
phosphatidylinositol 3-kinase (PI3K) and protein kinase B
(PKB)/Akt expression levels, resulting in upregulation of
cAMP response element-binding (CREB) and nuclear factor-
kappaB (NF-𝜅B) which translocate to the nucleus to act as A
3
adenosine receptor transcription factors [62].
Selective A
3
adenosine receptor agonists are being
developed for the treatment of inflammatory diseases
such as rheumatoid arthritis, osteoarthritis, psoriasis, and
inflammatory bowel diseases [66]. One of these ago-
nists is the compound CF101 (N6-(3-iodobenzyl)-5󸀠-N-
methylcarboxamidoadenosine) which exerts a robust anti-
inflammatory effect in experimental animal models of
inflammatory diseases [67–70]. The mechanism of action
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mediating the anti-inflammatory effect of CF101 includes
downregulation of NF-𝜅B signaling pathway, leading to
inhibition of proinflammatory cytokines (TNF-𝛼, IL-6, and
IL-12), macrophage inflammatory proteins (MIPs-1a,MIP-2),
and receptor activator ofNF-𝜅B ligand (RANKL), resulting in
apoptosis of inflammatory cells [68, 71]. In addition, a direct
antiproliferative effect of CF101 towards autoreactive T cells
has been observed [72].
The anti-inflammatory effects of CF101 via A
3
adenosine
receptor has prompted to explore its use for the treatment of
inflammatory ophthalmic diseases such as dry eye and uve-
oretinitis. Dry eye syndrome is an inflammatory condition
of the eye characterized by a massive production of proin-
flammatory cytokines [73–75].Desiccating stress induces tear
hyperosmolarity, activating intracellular signaling pathways
that initiate the production of proinflammatory cytokines.
These inflammatory mediators promote the activation (mat-
uration) of immature APCs and induce their migration
to draining lymphoid tissues. The APCs are responsible
for priming naive T cells in the lymphoid compartment,
leading to the expansion of autoreactive CD4+ helper T cell
(TH) subtype 1 and TH17 cell subsets. T cells subsequently
infiltrate the ocular surface, where they secrete additional
proinflammatory cytokines [76].
A phase II clinical study (randomized, multicenter,
double-masked, placebo-controlled, and parallel group)
exploring the effect of CF101 on patients with moderate
to severe dry eye syndrome has been performed. CF101
administrated orally (1mg/day for 12 weeks), induced a
statistically significant improvement in the corneal staining
and an improvement in the tear break-up time and tear
meniscus height in patients with dry eye syndrome [77]. In
good agreement with previous trials [78], the drug was very
well tolerated and no severe adverse effects were detected.
It has been suggested that the improvement in the corneal
staining and tear break-up time in the study group might
be due to reduced inflammation on the ocular surface
following direct interaction between CF101 and its receptors
on inflammatory cells [79]. However, additional proofs of
reduction of inflammation are required to fully confirm this
notion.
An experimental mice model of uveitis has been used
to test the anti-inflammatory action of CF101. Oral treat-
ment with CF101 (10 𝜇g/kg, twice daily), initiated upon
disease onset, improved uveitis clinical score measured by
fundoscopy and ameliorated the pathological manifestations
of the disease [72]. A decrease in PI3K and STAT (signal
transducer and activator of transcription) protein levels in the
lymph nodes of experimental autoimmune uveitis mice was
detected upon CF101 treatment. Both proteins are known to
be involved in the production of proinflammatory cytokines
[80, 81] and, indeed, inhibition of interleukin-2, TNF-𝛼, and
interferon-𝛾 (IFN-𝛾) production was also found in CF101-
treated animals [72]. Furthermore, CF101 suppressed the
antigen-specific proliferation of autoreactive T cells. Overall
these results indicate the marked anti-inflammatory effect
of CF101 and support further investigation of this drug for
uveitis treatment.
3. Ocular Sensory Innervation and
Purinergic Receptors P2 Involved in
Ocular Inflammation
The trigeminal ganglion through the ophthalmic nerve pro-
vides nonvisual sensory innervation of the eye. Sensory
neurons innervating the eye detect noxious or potentially
noxious stimuli in order to protect the eyeball, elaborate
responses to minimize damage, and promote tissue repair.
These sensory neurons transduce mechanical, thermal, and
chemical stimuli in the noxious range or close to it. Most
of the sensory nerve endings innervate the front of the eye,
in particular, the cornea and conjunctiva, but important
innervation is present in the uvea, where it has a critical role
on ocular inflammation [82].
Autonomic parasympathetic innervation of the eye is
supplied by the Edinger-Westphal nucleus in the brainstem
through the oculomotor nerve [83, 84]. Parasympathetic
nerve fibers synapse in the ciliary ganglion and enter the
ocular globe through the short ciliary nerves to innervate
the iris, the ciliary body and ciliary muscle, and parts
of the iridocorneal angle (uveal trabecular meshwork and
scleral spur). Some parasympathetic fibers come from the
pons through the geniculate ganglion (Petrosal). Later they
synapse in the pterygopalatine ganglion before entering the
eye [85]. In parallel, sympathetic nerve fibers arise from the
superior cervical ganglion and enter the eyeball though the
long and short ciliary nerves. They innervate the ciliary body
(central stroma and stroma of the ciliary processes), the iris,
andparts of the iridocorneal angle.Nonsignificant autonomic
innervation is present in the cornea, which is innervated
exclusively by sensory fibers.
Different studies have provided evidence for the presence
of purinergic receptors in sensory neurons from the trigem-
inal ganglion (Figure 1). P2X
3
receptor mRNA and protein
are found in the cell bodies of both small and large sensory
neurons, which has the highest level of expression among
these neurons and, in particular, in peptidergic neurons [86].
In contrast, only a small percentage of IB4-binding neurons
express this receptor in trigeminal ganglia. Lower levels are
found for P2X
1
, P2X
2
, P2X
4
, P2X
5
, and P2X
6
[86–88]. mRNA
and protein for P2Y
1
and P2Y
4
receptors are also present
and in many neurons, colocalized with P2X
3
receptors [89].
Despite the studies in trigeminal ganglion neurons, there
is a lack of specific studies on purinergic receptors in the
sensory nerve endings innervating the anterior part of the
eye (cornea, sclera, and conjunctiva) or the uvea (iris and
ciliary body). Although no information is available for ocular
nerves, purinergic receptors P2Y
1
, P2Y
2
, P2Y
4
, and P2Y
6
are
present in the corneal epithelium and endothelium cells [90]
(Figure 1). In fact, injury to corneal epithelial cells results in
nucleotide release and mobilization of a calcium wave from
the epithelium to the neurons [91]. It has been hypothesized
that ATP is initially released from epithelial cells and then
followed by a release of ATP and glutamate from neuronal
processes that activate purinergic and N-methyl-D-aspartate
(NMDA) receptors, contributing to the wound response [91].
In humans, P2X
7
receptor mRNA is also found in the cornea
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and upregulated in diabetic patients. Evidence indicates that
corneal epithelial cells express full-length and truncated
forms of P2X
7
, allowing P2X
7
to function as a multifaceted
receptor that can mediate cell proliferation and migration or
cell death [92].
In parallel, the conjunctiva, thewetmucosalmembrane of
the eye, is highly exposed to the environment and at the same
time very sensitive to the damaging effects of inflammation.
The ocular surface therefore requires a carefully balanced
mechanism to initiate inflammation only when absolutely
necessary. Here, hybridization to P2Y
2
receptor mRNA has
been observed in the palpebral and bulbar conjunctival
epithelium, including goblet cells, the corneal epithelium,
and in meibomian gland sebaceous and ductal cells [93]. In
addition, recent studies [94] have reported that the purinergic
receptors P2X
4
and P2X
7
and the bacterial Toll-like receptor
2 (TLR2) are present and functional in conjunctival goblet
cells and are involved in the priming and activation of the
NLRP3 inflammasome, initiated by danger associatedmolec-
ular patterns (DAMPs) such as ATP. The P2X
7
receptor-
NLRP3 inflammasome complex modulates the release of the
inflammatory cytokines IL-1b and IL-18 and it seems to be
involved in the primary Sjo¨gren’s syndrome pathology in the
salivary glands and likely in Sjo¨gren’s derived ocular dryness
(xerophthalmia) [95].
In the anterior uvea, purinergic receptors P2Y
1
, P2Y
2
, and
P2Y
4
have been found in the iris [90].The same receptors and
P2Y
11
have also been observed in both layers of the ciliary
body epithelium (pigmented and nonpigmented) in the
rabbit and monkey eye (Figure 1), in addition to a variety of
structures within the choroid [90, 93]. Functional evidence of
P2Y
2
receptor activity has also been reported in these tissues
[96, 97]. In turn, ocular ciliary epithelial cells are known to
store and release ATP, an endogenous P2Y
2
receptor agonist,
providing a potential source of extracellular nucleotides for
autocrine regulation of intraocular pressure [98]. In this
sense, ATP it is known to be released from antidromically
stimulated trigeminal sensory nerve endings in the ciliary
body and, as a consequence, a significant increase of ATP is
found in the aqueous humor [99].This provides evidence that
ATP released by ocular sensory innervation or after injury
of ocular tissues can activate both sensory nerve endings
and purinergic receptors present in the iris, ciliary body,
or other tissues surrounding the anterior chamber of the
eye to produce uveitis/endophthalmitis. In addition to the
cornea and sclera, abundant sensory nerve terminals are
present in the iris and anterior uvea, which detectmechanical,
thermal, and chemical stimuli, contributing to neurogenic
inflammation (inflammation of neural origin) by releasing
proinflammatory neuropeptides like substance P and CGRP
[82, 100]. As stated before, releasedATPmight stimulate these
sensory nerve endings to enhance neurogenic inflammation
and to maintain an inflamed state in the eye after a noxious
insult.
Circulating ATP, nucleotides, and dinucleotides released
into the aqueous humor can also stimulate purinergic recep-
tors present in the trabecular meshwork, a tissue located at
the iridocorneal angle of the anterior chamber of the eye
and involved in the regulation of aqueous humor outflow.
mRNA, protein, and functional evidence have been found
for purinergic receptors P2Y
1
, P2Y
2
, P2Y
4
, and P2Y
11
in
the bovine trabecular meshwork (Figure 1) [101, 102] and
in the human HTM-3 cell line [103]. Depending on the
purinergic receptor activated, an increase or decrease in
aqueous humor outflow is found. In this sense, selective
agonists of P2Y
1
receptor increase the facility of aqueous
humor outflow and have been proposed as possible drugs
for ocular hypertension [102]. On the other hand, ocular
inflammation/uveitis produces the opposite effect on outflow
facility (decrease) and it has been proposed that ATP and
other inflammatorymediatorsmight be involved in this effect
[101, 104–106].
4. Conclusions
The eye has evolved to curb intraocular inflammation
protecting the delicate visual elements from damage that
would be detrimental to visual acuity. This ability of the
eye to limit and control immune responses is known as
ocular immune privilege. However, the immune privilege can
fail and inflammatory processes can occur. The nucleoside
adenosine and nucleotides such as ATP are emerging as novel
molecules related to ocular inflammatory diseases. To date,
the anti-inflammatory effects of adenosine and their agonists
CGS21680 and CF101 acting via A
2A and A3 adenosine
receptors, respectively, have encouraged exploring their use
for the treatment of inflammatory ophthalmic conditions
such as ocular retinal pathologies and dry eye and clinical
trials are being developed. In contrast to adenosine, the
nucleotide ATP exhibits proinflammatory actions mediated
by purinergic P2 receptors present in sensory nerve endings
or in other eye locations. Altogether the effects of nucleotides
and dinucleotides suggest the development of some of these
compounds as therapeutic agents mainly based on the use
of P2 receptor antagonists. Also, indirectly, the use of P2Y
2
agonists on the ocular surface to treat dry eye could reduce
ocular surface inflammation, but it is necessary to be aware
that the anti-inflammatory effect is a consequence of the
restorage of aqueous andmucin production.Under these new
normal conditions, friction of the lids with the ocular surface
is diminished and therefore inflammation is reduced. In any
case, to our knowledge, apart from the commented effects on
dry eye, there is a lack of patents claiming the use of agonists
or antagonists for the treatment of ocular inflammation,
although, in the recent years, our knowledge about the rela-
tion of these molecules with ocular inflammatory processes
is increasing. However a better understanding of their exact
contribution in the different ocular inflammatory diseases
(dry eye, severe cicatrizing conjunctivitis, uveitis, and so
forth) is an important step to reveal additional pathologic
mechanisms and designing new therapies based on the use
of purinergic agonists and antagonists.
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